Abstract:The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million confirmed cases and 478,000 deaths (as of June 24th, 2020). The high intensive care unit (ICU) admission rate and mortality of COVID-19 is continuously posing a serious strain on the global health-care system. While most patients present with mild to moderate symptoms, some patients may develop life-threatening sepsis, respiratory failure, acute respiratory distress syndrome (ARDS) and multiple organ failure. However, current antiviral and supportive therapies are not sufficient to prevent or treat the above complications especially in severely ill COVID-19 patients [1]. Thus, it is urgent to find the underlying mechanism dominating such life-threatening complications. It is well recognized that lung damage and multi-organ failure in this subgroup of patients arise due to overwhelming systemic hyper-inflammation. Therefore, promising anti-inflammatory candidate agents targeting diverse mechanisms related to cytokine storm will be therapeutically relevant (Fig. 1 ). Open in a separate window Fig. 1 Potential therapies of COVID-19 by targeting inflammation and cytokine storm. SARS-CoV-2 enters and infects cells by binding to TMPRSS2 and ACE2, subsequently releases virus RNA, one of the PAMPs, and recruits dendritic cells, macrophages and neutrophils. The released type I interferon and pro-inflammatory cytokines and chemokines induce the innate immune response while adaptive immune response is ignited by activating T and B lymphocytes to defend against the virus. Meanwhile, intact viruses or the components can directly activate the NLRP3 inflammasome, leading to IL-1β secretion. In most infections, moderate immune response and antiviral response are capable to combat the infection. Nevertheless, in individuals with immunological dysfunction, persistent hyper-inflammation triggers a cytokine storm, leading to the lung injury and ARDS or eventually swept through the whole body, causing MODS. During the pathological progression, the inhibition of NRLP3, JAK1/2, IL-6, BRD4 and the infusion of IVIG may be beneficial in suppressing the overwhelming inflammation and arrest or reverse the COVID-19 disease. Abbreviations: ACE2, angiotensin converting enzyme 2; ARDS, acute respiratory distress syndrome; IVIG, intravenous immunoglobulin; MODS, multiple organ dysfunction syndrome; NLRP3, Nod-like receptor protein 3; PAMP, pathogen-associated molecular pattern; TMPRSS2, transmembrane serine protease 2.

Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19

Alveolar Macrophage Dysfunction and Cytokine Storm in the Pathogenesis of Two Severe COVID-19 Patients.

The Mechanism of Multiple Organ Dysfunction Syndrome in Patients with COVID‐19

The mechanism of multiple organ dysfunction syndrome in patients with COVID-19

SARS-CoV-2 Infection Triggers Profibrotic Macrophage Responses and Lung Fibrosis

Clinical and Pathological Investigation of Patients with Severe COVID-19

Pathogenic T-cells and Inflammatory Monocytes Incite Inflammatory Storms in Severe COVID-19 Patients

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Autopsy analysis reveals increased macrophage infiltration and cell apoptosis in COVID-19 patients with severe pulmonary fibrosis

Targeting Inflammation and Cytokine Storm in COVID-19

Pathogenic neutrophilia drives acute respiratory distress syndrome in severe COVID-19 patients

The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections

Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia

Preventing the Development of Severe COVID-19 by Modifying Immunothrombosis

Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration

Ligand/Receptor-mediated Cell Communication Alteration Causes the Lung Inflammation Microenvironment and the Redistribution of Inter-tissue Immune Cells in COVID-19 Patients

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Cytokine Storm Induced by SARS-CoV-2

The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach

The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19